China To Implement New Regulations For Patent Law; Companies Should Set Up Inventor Reward Policy To Prepare For Changes
This article was originally published in PharmAsia News
SHANGHAI - China's State Council recently approved new implementation regulations for the country's Patent law, which clarifies procedural issues in line with new changes to the patent law that took effect last year
You may also be interested in...
Exclusive: U.S. Chamber Lobbies Against China Drug Registration Revisions That Would Favor Local Generics
The U.S. Chamber of Commerce is lobbying China FDA over its recent draft drug registration regulations, which would allow approval of generics while an originator’s patent is still valid. Big pharma could face faster and stronger generic competition in China if CFDA finalizes the regulations without revision.
China FDA released a draft regulation on drug registration that formalizes the “Bolar Exemption,” but the approach taken is unbalanced, according to experts, and would end up favoring generic competitors.
Lee Babiss left his position as president of pharmaceutical research at Roche to become the executive vice president of global laboratory services at the Wilmington, North Carolina-based contract research organization PPD. In part one of an interview with PharmAsia News, Babiss spoke about the evolving relationships between pharmaceutical firms and CROs, including end-to-end virtualization of R&D (PharmAsia News, April 6, 2010).